Published in Mol Ther on February 01, 2000
Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol (2001) 3.38
Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial. Hum Gene Ther (2011) 2.29
Successful treatment of canine hemophilia by continuous expression of canine FVIIa. Blood (2008) 2.01
Treatment of human disease by adeno-associated viral gene transfer. Hum Genet (2006) 1.84
Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance. Am J Hum Genet (2007) 1.76
Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy. Mol Ther (2010) 1.63
Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins. J Clin Invest (2002) 1.63
The complex and evolving story of T cell activation to AAV vector-encoded transgene products. Mol Ther (2010) 1.55
Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. J Clin Invest (2009) 1.54
Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency. ILAR J (2009) 1.43
Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice. Proc Natl Acad Sci U S A (2001) 1.40
Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease. Mol Ther (2009) 1.34
Adeno-associated virus vectors: potential applications for cancer gene therapy. Cancer Gene Ther (2005) 1.19
Parkinson's disease gene therapy: success by design meets failure by efficacy. Mol Ther (2013) 1.18
Strategies to modulate immune responses: a new frontier for gene therapy. Mol Ther (2009) 1.14
Understanding hereditary diseases using the dog and human as companion model systems. Mamm Genome (2007) 1.09
Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease. Hum Gene Ther (2012) 1.08
Tolerance induction by viral in vivo gene transfer. Clin Med Res (2005) 1.07
Evaluation of adeno-associated viral vectors for liver-directed gene transfer in dogs. Hum Gene Ther (2011) 1.05
Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II. Mol Ther (2006) 0.99
Translational data from adeno-associated virus-mediated gene therapy of hemophilia B in dogs. Hum Gene Ther Clin Dev (2015) 0.95
Immunomodulatory gene therapy in lysosomal storage disorders. Curr Gene Ther (2009) 0.92
Muscle-directed gene therapy for hemophilia B with more efficient and less immunogenic AAV vectors. J Thromb Haemost (2011) 0.90
Liver-Directed Adeno-Associated Viral Gene Therapy for Hemophilia. J Genet Syndr Gene Ther (2012) 0.90
Animal models of hemophilia and related bleeding disorders. Semin Hematol (2013) 0.89
Efficient AAV1-AAV2 hybrid vector for gene therapy of hemophilia. Hum Gene Ther (2006) 0.88
AAV-mediated liver-directed gene therapy. Methods Mol Biol (2011) 0.88
AAV-mediated expression of an ADAMTS13 variant prevents shigatoxin-induced thrombotic thrombocytopenic purpura. Blood (2013) 0.87
Feasibility of generating adeno-associated virus packaging cell lines containing inducible adenovirus helper genes. J Virol (2002) 0.84
Preexisting Neutralizing Antibodies to Adeno-Associated Virus Capsids in Large Animals Other Than Monkeys May Confound In Vivo Gene Therapy Studies. Hum Gene Ther Methods (2015) 0.83
Impaired clearance of accumulated lysosomal glycogen in advanced Pompe disease despite high-level vector-mediated transgene expression. J Gene Med (2009) 0.83
Intramuscular injection of AAV8 in mice and macaques is associated with substantial hepatic targeting and transgene expression. PLoS One (2014) 0.83
Coagulation Factor IX for Hemophilia B Therapy. Acta Naturae (2012) 0.79
AAV Gene Therapy for Liver Disease. Hum Gene Ther (2016) 0.79
Gene therapy for lipid disorders. Curr Control Trials Cardiovasc Med (2000) 0.77
Gene delivery to the rat liver using cationic lipid emulsion/DNA complex: comparison between intra-arterial, intraportal and intravenous administration. Korean J Radiol (2002) 0.77
Gene therapy for hemophilia: a step closer to reality. Mol Ther (2000) 0.75
In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science (1996) 28.95
Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science (1996) 12.23
Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A (1996) 9.15
Platelet-derived growth factor induces rapid but transient expression of the c-fos gene and protein. Nature (1985) 8.36
Generation of helper-free amphotropic retroviruses that transduce a dominant-acting, methotrexate-resistant dihydrofolate reductase gene. Mol Cell Biol (1985) 7.49
The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses. J Virol (1996) 6.62
Development of a self-inactivating lentivirus vector. J Virol (1998) 6.60
Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science (1999) 6.20
FBJ murine osteosarcoma virus: identification and molecular cloning of biologically active proviral DNA. J Virol (1982) 6.11
Gene therapy -- promises, problems and prospects. Nature (1997) 6.02
Analysis of FBJ-MuSV provirus and c-fos (mouse) gene reveals that viral and cellular fos gene products have different carboxy termini. Cell (1983) 5.79
Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell (1990) 5.59
c-fos protein can induce cellular transformation: a novel mechanism of activation of a cellular oncogene. Cell (1984) 5.55
Nucleotide sequence of the genome of a murine sarcoma virus. Cell (1981) 5.48
Induction of proto-oncogene JUN/AP-1 by serum and TPA. Nature (1988) 5.18
Viral and cellular fos proteins: a comparative analysis. Cell (1984) 4.89
Expression of the c-fos gene and of an fos-related gene is stimulated by platelet-derived growth factor. Science (1984) 4.87
Structural alteration of viral homologue of receptor proto-oncogene fms at carboxyl terminus. Nature (1986) 4.70
Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med (1999) 4.61
Expression of cellular oncogenes in human malignancies. Science (1984) 4.48
Differential expression of cellular oncogenes during pre- and postnatal development of the mouse. Nature (1982) 4.44
Complete nucleotide sequence of a human c-onc gene: deduced amino acid sequence of the human c-fos protein. Proc Natl Acad Sci U S A (1983) 4.38
Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet (1997) 4.26
The reverse transcriptase. Biochim Biophys Acta (1977) 4.16
Transcriptional autoregulation of the proto-oncogene fos. Nature (1988) 4.10
Long terminal repeat of murine retroviral DNAs: sequence analysis, host-proviral junctions, and preintegration site. J Virol (1982) 4.06
Nucleotide sequence and formation of the transforming gene of a mouse sarcoma virus. Nature (1981) 4.05
In vitro synthesis of DNA complementary to rabbit reticulocyte 10S RNA. Nat New Biol (1972) 4.01
Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci U S A (1995) 3.90
fos-associated cellular p39 is related to nuclear transcription factor AP-1. Cell (1988) 3.82
Rapid induction of the expression of proto-oncogene fos during human monocytic differentiation. Cell (1985) 3.81
Transcriptional activation by BRCA1. Nature (1996) 3.64
Functional antagonism between c-Jun and MyoD proteins: a direct physical association. Cell (1992) 3.55
Structure of Moloney murine leukemia viral DNA: nucleotide sequence of the 5' long terminal repeat and adjacent cellular sequences. Proc Natl Acad Sci U S A (1980) 3.53
The rel-associated pp40 protein prevents DNA binding of Rel and NF-kappa B: relationship with I kappa B beta and regulation by phosphorylation. Genes Dev (1991) 3.52
Direct interaction between fos and jun nuclear oncoproteins: role of the 'leucine zipper' domain. Nature (1988) 3.43
Analysis of the env gene of a molecularly cloned and biologically active Moloney mink cell focus-forming proviral DNA. J Virol (1982) 3.40
Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc Natl Acad Sci U S A (1997) 3.40
Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med (1999) 3.39
Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol (1997) 3.37
Studies on reverse transcriptase of RNA tumor viruses III. Properties of purified Moloney murine leukemia virus DNA polymerase and associated RNase H. J Virol (1975) 3.31
A transmissible retrovirus expressing human hypoxanthine phosphoribosyltransferase (HPRT): gene transfer into cells obtained from humans deficient in HPRT. Proc Natl Acad Sci U S A (1983) 3.31
Covalently linked RNA-DNA molecule as initial product of RNA tumour virus DNA polymerase. Nat New Biol (1971) 3.27
I kappa B gamma, a 70 kd protein identical to the C-terminal half of p110 NF-kappa B: a new member of the I kappa B family. Cell (1992) 3.25
c-fos promoter trans-activation by the tax1 protein of human T-cell leukemia virus type I. Proc Natl Acad Sci U S A (1988) 3.24
Autoregulation of I kappa B alpha activity. Proc Natl Acad Sci U S A (1994) 3.24
Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc Natl Acad Sci U S A (2001) 3.24
Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science (1999) 3.10
Two base changes restore infectivity to a noninfectious molecular clone of Moloney murine leukemia virus (pMLV-1). J Virol (1984) 3.09
In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. Science (1993) 2.95
Removal of a 67-base-pair sequence in the noncoding region of protooncogene fos converts it to a transforming gene. Proc Natl Acad Sci U S A (1985) 2.95
Regulated mRNA stability. Annu Rev Genet (1990) 2.93
IKK1-deficient mice exhibit abnormal development of skin and skeleton. Genes Dev (1999) 2.92
Nucleotide sequence of Moloney leukemia virus: 3' end reveals details of replications, analogy to bacterial transposons, and an unexpected gene. Proc Natl Acad Sci U S A (1980) 2.90
Viral and cellular fos proteins are complexed with a 39,000-dalton cellular protein. Mol Cell Biol (1985) 2.86
Retinoic acid is a negative regulator of AP-1-responsive genes. Proc Natl Acad Sci U S A (1991) 2.85
Nuclear proto-oncogenes fos and jun. Annu Rev Cell Biol (1990) 2.82
Heteroduplex analysis of the sequence relations between the RNAs of mink cell focus-inducing and murine leukemia viruses. J Virol (1978) 2.79
Expression cloning of human EGF receptor complementary DNA: gene amplification and three related messenger RNA products in A431 cells. Science (1984) 2.75
Induction of the proto-oncogene fos by nerve growth factor. Proc Natl Acad Sci U S A (1985) 2.74
M-MuLV-induced leukemogenesis: integration and structure of recombinant proviruses in tumors. Cell (1981) 2.65
c-rel activates but v-rel suppresses transcription from kappa B sites. Proc Natl Acad Sci U S A (1991) 2.65
Gene therapy: trials and tribulations. Nat Rev Genet (2000) 2.62
Studies on the reverse transcriptase of RNA tumor viruses. Structural relatedness of two subunits of avian RNA tumor viruses. Proc Natl Acad Sci U S A (1974) 2.60
Cationic liposome-mediated RNA transfection. Proc Natl Acad Sci U S A (1989) 2.55
Structure of the FBJ murine osteosarcoma virus genome: molecular cloning of its associated helper virus and the cellular homolog of the v-fos gene from mouse and human cells. Mol Cell Biol (1983) 2.53
Expression of a retrovirus encoding human HPRT in mice. Science (1984) 2.48
Delivery of the Cre recombinase by a self-deleting lentiviral vector: efficient gene targeting in vivo. Proc Natl Acad Sci U S A (2001) 2.48
The mouse c-rel protein has an N-terminal regulatory domain and a C-terminal transcriptional transactivation domain. Mol Cell Biol (1990) 2.47
Modification of fos proteins: phosphorylation of c-fos, but not v-fos, is stimulated by 12-tetradecanoyl-phorbol-13-acetate and serum. Mol Cell Biol (1987) 2.40
Identification of a transcriptional enhancer element upstream from the proto-oncogene fos. Science (1985) 2.39
Induction of proto-oncogene fos transcription through the adenylate cyclase pathway: characterization of a cAMP-responsive element. Genes Dev (1988) 2.38
mXBP/CRE-BP2 and c-Jun form a complex which binds to the cyclic AMP, but not to the 12-O-tetradecanoylphorbol-13-acetate, response element. Mol Cell Biol (1990) 2.38
Long-term in vivo expression of retrovirus-mediated gene transfer in mouse fibroblast implants. Proc Natl Acad Sci U S A (1991) 2.34
Gene therapy via primary myoblasts: long-term expression of factor IX protein following transplantation in vivo. Proc Natl Acad Sci U S A (1992) 2.30
Direct association of pp40/I kappa B beta with rel/NF-kappa B transcription factors: role of ankyrin repeats in the inhibition of DNA binding activity. Proc Natl Acad Sci U S A (1992) 2.29
Detection of a transforming gene product in cells transformed by Moloney murine sarcoma virus. Cell (1982) 2.27
A factor IX-deficient mouse model for hemophilia B gene therapy. Proc Natl Acad Sci U S A (1997) 2.22
Identification of a RNA polymerase II initiation site in the long terminal repeat of Moloney murine leukemia viral DNA. Proc Natl Acad Sci U S A (1981) 2.16
Transcription of c-onc genes c-rasKi and c-fms during mouse development. Mol Cell Biol (1983) 2.14
Tumor necrosis factor alpha-induced phosphorylation of I kappa B alpha is a signal for its degradation but not dissociation from NF-kappa B. Proc Natl Acad Sci U S A (1994) 2.12
Both the basic region and the 'leucine zipper' domain of the cyclic AMP response element binding (CREB) protein are essential for transcriptional activation. EMBO J (1990) 2.11
Molecular cloning of unintegrated and a portion of integrated moloney murine leukemia viral DNA in bacteriophage lambda. J Virol (1980) 2.10
Expression of c-onc genes: c-fos transcripts accumulate to high levels during development of mouse placenta, yolk sac and amnion. EMBO J (1983) 2.08
Role of Rel/NF-kappaB transcription factors during the outgrowth of the vertebrate limb. Nature (1998) 2.08
Fos-Jun interaction: mutational analysis of the leucine zipper domain of both proteins. Genes Dev (1989) 2.06
Reciprocal role of ERK and NF-kappaB pathways in survival and activation of osteoclasts. J Cell Biol (2000) 2.04
BRCA1 is a cell cycle-regulated nuclear phosphoprotein. Proc Natl Acad Sci U S A (1997) 2.02
Identification and molecular cloning of Moloney mouse sarcoma virus-specific sequences from uninfected mouse cells. Proc Natl Acad Sci U S A (1980) 1.98
Complete lack of NF-kappaB activity in IKK1 and IKK2 double-deficient mice: additional defect in neurulation. Genes Dev (2000) 1.96
Association between proto-oncoprotein Rel and TATA-binding protein mediates transcriptional activation by NF-kappa B. Nature (1993) 1.94
Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc Natl Acad Sci U S A (1999) 1.90
Size analysis and relationship of murine leukemia virus-specific mRNA's: evidence for transposition of sequences during synthesis and processing of subgenomic mRNA. J Virol (1978) 1.90
DNA polymerase activity from two temperature-sensitive mutants of Rous sarcoma virus is thermolabile. Nature (1974) 1.90
Qualitative changes in the subunit composition of kappa B-binding complexes during murine B-cell differentiation. Proc Natl Acad Sci U S A (1994) 1.89
Overdosage of opiate from patient controlled analgesia devices. BMJ (1994) 1.89